- Home
- ZNTL vs GALT Comparison
ZNTL vs GALT Comparison
Compare ZNTL & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | GALT |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 176.7M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | GALT |
|---|---|---|
| Price | $2.49 | $3.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $6.60 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 623.6K | 231.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,425,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.15 |
| 52 Week High | $3.95 | $7.13 |
Technical Indicators
Market Signals| Indicator | ZNTL | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 48.30 |
| Support Level | $1.27 | $2.90 |
| Resistance Level | $2.69 | $3.24 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 55.17 | 62.86 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.